A Phase II Study on Recombinant Botulinum Toxin Type a (YY001) for Injection in the Treatment of Upper Limb Spasticity in Adults
- Conditions
- Upper Limb Spasticity
- Interventions
- Biological: Recombinant Botulinum Toxin Type A for injection (YY001)Biological: Placebo
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT06783114
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳RenMin Hospital Of Wuhan University, Wuhan, Hubei, China
🇨🇳The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines
- Conditions
- Moderate to Severe Glabellar Lines
- Interventions
- Biological: Rcombinant botulinum neurotoxin type A for injection (YY001)
- First Posted Date
- 2024-09-04
- Last Posted Date
- 2024-09-04
- Lead Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
- Target Recruit Count
- 488
- Registration Number
- NCT06583486
- Locations
- 🇨🇳
Guangdong Second People's Hospital, Guangzhou, Guangdong, China
🇨🇳Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
🇨🇳The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines
- Conditions
- Moderate to Severe Glabellar Lines
- Interventions
- Biological: PlaceboBiological: Rcombinant botulinum neurotoxin type A for injection (YY001)Biological: OnabotulinumtoxinA
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
- Target Recruit Count
- 529
- Registration Number
- NCT06499688
- Locations
- 🇨🇳
West China School of Medicine/West China Hospital of Sichuan University, Chengdu, Sichuan, China
🇨🇳Zhejiang Provincial People's Hospital, :Hangzhou, Zhejiang, China
🇨🇳Guangdong Second People's Hospital, Guangzhou, Guangdong, China
A Study to Investigate the Safety and Efficacy of YY003 in Adults with Moderate to Severe Glabellar Lines
- Conditions
- Moderate to Severe Glabellar Lines
- Interventions
- Biological: Vehicle Control
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
- Target Recruit Count
- 174
- Registration Number
- NCT06481475
- Locations
- 🇦🇺
St George Dermatology & Skin Cancer Centre, Sydney, New South Wales, Australia
🇦🇺Skin Health Institute, Melbourne, Victoria, Australia
🇦🇺Dermatology Institute of Victoria, Melbourne, Victoria, Australia
A Phase I/II Study of Recombinant Botulinum Toxin Type A for the Treatment of Moderate to Severe Glabellar Lines
- Conditions
- Moderate to Severe Glabellar Lines
- Interventions
- Biological: OnabotulinumtoxinABiological: YY001Biological: Placebo
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
- Target Recruit Count
- 140
- Registration Number
- NCT05743634
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳West China Hospital,Sichuan University, Chengdu, Sichuan, China
🇨🇳The First affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China